Galenica and Roche strike Mircera deal
This article was originally published in Scrip
Executive Summary
Swiss firms Roche and Galenica have inked a licensing deal that will see the latter exclusively commercialize in the US and Puerto Rico Roche's Mircera (methoxy polyethylene glycol-epoetin beta), a treatment for symptomatic anemia associated with chronic kidney disease.